Last reviewed · How we verify
SOLIFENACIN SUCCINATE
SOLIFENACIN SUCCINATE is a drug. It is currently FDA-approved (first approved 2004) for Overactive Bladder.
Solifenacin blocks muscarinic receptors, reducing urinary bladder smooth muscle contractions.
Solifenacin succinate is a small molecule that acts as a muscarinic acetylcholine receptor M3 antagonist. It is used to treat overactive bladder, a condition characterized by involuntary contractions of the bladder muscle.
At a glance
| Generic name | SOLIFENACIN SUCCINATE |
|---|---|
| Target | Muscarinic receptors |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2004 |
Mechanism of action
Solifenacin works by blocking muscarinic receptors, which are involved in various cholinergic functions. By doing so, it reduces the contractions of the urinary bladder smooth muscle, helping to manage overactive bladder symptoms.
Approved indications
- Overactive Bladder
Common side effects
- Dry Mouth
- Dry Mouth
- Constipation
- Constipation
- Nausea
- Dyspepsia
- Abdominal Pain Upper
- Vomiting NOS
- Urinary Tract Infection NOS
- Urinary Tract Infection NOS
- Influenza
- Pharyngitis NOS
Drug interactions
- strong CYP3A4 inhibitors (e.g., ketoconazole)
Key clinical trials
- Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women (PHASE4)
- Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients (PHASE2)
- Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women (PHASE3)
- Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study (PHASE4)
- Mirabegron in Patients With Age-Related Macular Degeneration
- Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
- Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females (NA)
- Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOLIFENACIN SUCCINATE CI brief — competitive landscape report
- SOLIFENACIN SUCCINATE updates RSS · CI watch RSS
Frequently asked questions about SOLIFENACIN SUCCINATE
What is SOLIFENACIN SUCCINATE?
How does SOLIFENACIN SUCCINATE work?
What is SOLIFENACIN SUCCINATE used for?
When was SOLIFENACIN SUCCINATE approved?
What development phase is SOLIFENACIN SUCCINATE in?
What are the side effects of SOLIFENACIN SUCCINATE?
What does SOLIFENACIN SUCCINATE target?
Related
- Target: All drugs targeting Muscarinic receptors
- Indication: Drugs for Overactive Bladder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing